KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Finished Goods (2018 - 2025)

Ionis Pharmaceuticals (IONS) has disclosed Finished Goods for 8 consecutive years, with $2.1 million as the latest value for Q1 2025.

  • For Q1 2025, Finished Goods rose 959.0% year-over-year to $2.1 million; the TTM value through Mar 2025 reached $2.1 million, up 959.0%, while the annual FY2024 figure was $276000.0, 79.22% up from the prior year.
  • Finished Goods hit $2.1 million in Q1 2025 for Ionis Pharmaceuticals, up from $276000.0 in the prior quarter.
  • Across five years, Finished Goods topped out at $2.1 million in Q1 2025 and bottomed at $63000.0 in Q3 2024.
  • Average Finished Goods over 5 years is $563294.1, with a median of $288000.0 recorded in 2022.
  • Year-over-year, Finished Goods crashed 87.02% in 2021 and then surged 959.0% in 2025.
  • Ionis Pharmaceuticals' Finished Goods stood at $390000.0 in 2021, then crashed by 57.95% to $164000.0 in 2022, then fell by 6.1% to $154000.0 in 2023, then soared by 79.22% to $276000.0 in 2024, then soared by 667.39% to $2.1 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $2.1 million, $276000.0, and $63000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.